Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer

Cancer Research

Volumn 62, Issue 19, 2002, Pages 5485-5488

  Mendoza, Nerissa ^a   Phillips, Gail Lewis ^a   Silva, Johnny ^a   Schwall, Ralph ^a   Wickramasinghe, Dineli ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND; MONOCLONAL ANTIBODY; NEU DIFFERENTIATION FACTOR; PERTUZUMAB; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; ONCOGENE NEU; PHOSPHORYLATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGENS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; LIGANDS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; NEUREGULIN-1; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECOMBINANT PROTEINS; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036792117     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Craft, N., Shostak, Y., Carey, M., and Sawyers, C. L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med., 5: 280-285, 1999.
2. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ulrich, A., and McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC), 235: 177-182, 1987.
3. Scher, H. I. HER2 in prostate cancer - a viable target or innocent bystander? J. Natl. Cancer Inst. (Bethesda). 92: 1866-1867, 2000.
4. Signoretti, S., Monitroni, R., Manola, J., Altimari, A., Tam, C., Bubley, G., Balk, S., Thomas, G., Kaplan, I., Hlatky, L., et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst. (Bethesda), 92: 1918-1925, 2000.
5. Carraway, K. L., Sliwkowski, M. X., Akita, R. W., Platko, J. V., Guy, P. M., Nuijens, A., Diamonti, A. J., Vandlen, R. L., Cantley, L. C., and Cerione, R. A. The erbB3 gene product is a receptor for heregulin. J. Biol. Chem., 269: 14303-14306, 1994.
6. Sliwkowski, M. X., Schaefer, G., Akita, R. W., Lofgren, J. A., Fitzpatrick, V. D., Nuijens, A., Fendly, B. M., Cerione, R. A., Vandlen, R. L., and Carraway, K. L. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem., 26: 14661-14665, 1994.
7. Lewis, G. D., Lofgren, J. A., McMurtrey, A. E., Nuijens, A., Fendly, B. M., Bauer, K. D., and Sliwkowski, M. X. Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res., 56: 1457-1465, 1996.
8. Westphal, M., Meima, L., Szonyi, E., Lofgren, J., Meissner, H., Hamel, W., Nikolics, K., and Sliwkowski, M. X. Heregulins and the ErbB-2/3/4 receptors in gliomas. J. Neurooncol., 35: 335-346, 1997.
9. Xu, F., Yu, Y., Le, X. F., Boyer, C., Mills, G. B., and Bast, R. C. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin. Cancer Res., 5: 3653-3660, 1999.
10. Venkateswarlu, S., Dawson, D. M., St Clair, P., Gupta, A., Willson, J. K., and Brattain, M. G. Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene, 21: 78-86, 2002.
11. Sramkoski, R. M., Pretlow, T. G., Giaconia, J. M., Pretlow, T. P., Schwartz, S., Sy, M. S., Marengo, S. R., Rhim, J. S., Zhang, D., and Jacobberger, J. W. A new human prostate carcinoma cell line. 22Rv1. In Vitro Cell. Dev. Biol. Anim., 35: 403-409, 1999.
12. Pretlow, T. G., Wolman, S. R., Micale, M. A., Pelley, R. J., Kursh, E. D., Resnick, M. I. Bodner, D. T., Jacobberger, J. W., Delmoro, C. M., Giaconia, J. M., et al. Xenografts of primary human prostatic carcinoma. J. Natl. Cancer Inst. (Bethesda). 85: 394-398, 1993.
13. Nagabhushan, M., Miller, C. M., Pretlow, T. P., Giaconia, J. M., Edgehouse, N. L., Schwartz, S., Kung, H. J., deVere White, R. W., Gumerlock, P. H., Resnick, M. I., Amini, S. B., and Pretlow, T. G. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res., 56: 3042-3046, 1996.
14. Fendly, B. M., Winget, M., Hudziak, R. M., Lipari, M. T., Napier, M. A., and Ullrich, A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res., 50: 1550-1558, 1990.
15. Wainstein, M. A., He, F., Robinson, D., Kung, H. J., Schwartz, S., Giaconia, J. M., Edgehouse, N. L., Pretlow, T. P., Bodner, D. R., Kursh, E. D., et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res., 54: 6049-6052, 1994.
16. Harwerth, I., M., Wels, W., Marte, B. M., and Hynes, N. E. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumor cell growth. J. Biol. Chem., 267: 15160-15167, 1992.
17. Robinson, D., He, F., Pretlow, T. G., and Kung, H. J. A tyrosine kinase profile of prostate carcinoma. Proc. Natl. Acad. Sci. USA, 93: 5958-5962, 1996.
18. Agus, D. B., Scher, H. I., Higgins, B., Fox, W. D., Heller, G., Fazzari, M., Cordon-Cardo, C., and Golde, D. W. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res., 59: 4761-4764, 1999.
19. Agus, D. B., Akita, R. W., Fox, W. D., Lofgren, J. A., Higgins, B., Maiese, K., Scher, H. I., and Sliwkowski M. X. A potential role for activated HER-2 in prostate cancer. Semin. Oncol., 27: 76-83, 2000.
20. Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindall, C., Evans, D. P., Maiese, K., Scher, H. I., and Sliwkowski, M. X. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth, Cancer Cell. In press, 2002.